Manufactures active pharmaceutical ingredients (APIs) for the global animal health and human pharma industries, running 5 production facilities in India with FY26 revenue of Rs.500.95 crore. Animal health APIs account for 95% of Q4 FY26 revenues, supplying 5 of the world's top 10 animal health companies and serving roughly 430 customers across 54-55 countries; exports make up 75% of revenue. The product portfolio has grown from about 20 APIs three years ago to 45 APIs, with a stated target of 9-10 new APIs added annually, and the customer base widened by 47 new accounts in Q4 FY26. Manufacturing capacity is being expanded in two phases at Tarapur: Phase I is operational at 70-80% utilisation, while Phase II commissioning is now slated for early Q2 FY27 with commercial production targeted from H2 FY27; total Phase II capex is Rs.210 crore (Rs.182.75 crore spent), with the new plant expected to generate Rs.350-400 crore of revenue at peak over 3-4 years. Regulated-market access is being built through 5 VMFs filed with the US FDA (6 more planned), 6 CEPs and 9 DMS targeted by end CY2026, with Europe sales starting in CY2026 and US sales from FY28. Raw materials are the largest input cost at 49.3% of revenue, followed by other operating expenses at 24.6% and employee costs at 13.1%. AR · MarketPing reader · 2026-08-02
Revenue streams, as the annual report describes them. Animal health APIs (95%), Human health APIs (5%), Export sales (75%). B2B API manufacturer; export-heavy; animal-health-focused; capacity-expanding
| ₹ crore · consolidated | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | 318 | 278 | 339 | 368 | 501 |
| EBITDA (ex other income) | 68 | 34 | 53 | 34 | 73 |
| margin % | 21.4 | 12.3 | 15.7 | 9.2 | 14.5 |
| Owners' profit | 0 | 0 | 0 | 21 | 0 |
| EPS, as reported (₹) | 80.77 | 33.18 | 66.88 | 34.19 | 77.90 |
| ROE % · ROCE % | 24.6 · 32.3 | 9.2 · 12.5 | 15.7 · 20.7 | 7.5 · 9.6 | 14.6 · 17.2 |
| Debt / equity (x) | 0.13 | 0.14 | 0.12 | 0.26 | 0.33 |
| Cash from operations | 14 | 35 | 20 | 36 | 43 |
| Capex | (56) | (31) | (29) | (131) | (90) |
| ₹ crore | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 93 | 89 | 95 | 104 | 120 | 128 | 149 | 139 |
| Profit before tax | 13 | 1 | 1 | 12 | 13 | 21 | 18 | 24 |
| Net profit | 10 | 1 | 1 | 9 | 10 | 16 | 13 | 18 |
| EPS (₹) | 15.88 | 2.07 | 0.88 | 14.96 | 15.58 | 25.40 | 21.83 | 29.78 |
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| SUN PHARMACEUTICAL IND L | 4,41,471 | 36.5 | 5.26 | 23.7 | 13.7 | 17.5 | 11.8 | 32.3 |
| DIVI S LABORATORIES LTD | 2,47,033 | 84.6 | 14.74 | 63.7 | 15.3 | 18.8 | 8.7 | 42.8 |
| TORRENT PHARMACEUTICALS L | 1,68,062 | 79.3 | 9.56 | 41.5 | 12.2 | 8.0 | 11.8 | 33.1 |
| ZYDUS LIFESCIENCES LTD | 1,11,686 | 24.9 | 3.78 | 14.5 | 17.3 | 18.0 | 12.4 |
| Date · filing | Category | Importance | 1-day % | 5-day % |
|---|---|---|---|---|
| 10 Sept 2026 · NGL Fine Chem schedules one-to-one virtual analyst meet on Sept 16 | board shareholder meetings | low | — | — |
| 27 Aug 2026 · NGL Fine Chem 45th AGM: All 6 resolutions passed | compliance | minimal | — | — |
| 25 Aug 2026 · 45th AGM held; Final Dividend declared; two directors reappointed | board shareholder meetings | medium | — | — |
| 20 Aug 2026 · Corrigendum to Annual Report CSR figures unit corrected from Crores to Lakhs | general | low | — | — |
| 17 Aug 2026 · NGL Fine-Chem Q1FY27: Revenue up 34% YoY, PAT nearly doubles | investor communications | medium | — | — |
| 12 Aug 2026 · NGL Fine Chem board responds to exchange fines for delayed filing | regulatory legal | medium | — | — |
| 12 Aug 2026 · NGL Fine Chem Q1 FY27 results: revenue up 34%, profit doubles YoY | results | high | — | — |
| 12 Aug 2026 · NGL Fine Chem Q1 FY27 results: Revenue up 34%, PAT nearly doubles YoY | results | high | — | — |
| 4 Aug 2026 · NGL Fine Chem: 45th AGM notice published, book closure Aug 19-25 | compliance | minimal | — | — |
| 31 Jul 2026 · NGL Fine-Chem files BRSR for FY 2025-26 | compliance | low | — | — |
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions |
| 25.2 |
| CIPLA LTD | 1,10,352 | 32.7 | 3.20 | 16.9 | 11.2 | 14.7 | 8.0 | 19.7 |
| LAURUS LABS LIMITED | 1,06,375 | 97.2 | 19.59 | 59.3 | 16.4 | 17.2 | 7.2 | 32.0 |
| DR. REDDY S LABORATORIES | 97,319 | 30.1 | 2.55 | 13.1 | 10.9 | 13.0 | 12.1 | 15.0 |
| AUROBINDO PHARMA LTD | 96,656 | 26.3 | 2.55 | 13.4 | 9.2 | 12.6 | 6.3 | 23.0 |
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 29.2 | 28.9 | 86 of 169 | 49% |
| P/B | 5.1 | 3.3 | 115 of 163 | 30% |
| ROCE | 16.0 | 10.8 | 53 of 183 | 71% |
| ROE | 14.6 | 10.4 | 52 of 171 | 70% |
| Debt / Equity | 0.3 | 0.1 | 124 of 171 | 28% |
| EBITDA margin | 22.1 | 17.5 | 66 of 165 | 60% |
| Revenue growth | 33.6 | 16.3 | 41 of 161 | 75% |
| Profit growth | 99.1 | 30.9 | 37 of 158 | 77% |
| Market cap | 1668 | 839 | 81 of 182 | 56% |
| an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
